Guidelines for management of androgenetic alopecia based on BASP classification–the Asian consensus committee guideline

Lee, Woo Seung; Lee, H.J.; Choi, Gwang Seong; Cheong, Wai Kwong; Chow, Sam; Gabriel, Ma. Teresita G.; Hau, K.L.; Kang, Hoon; Mallari, Margaret; Tsai, Ren‐Yeu; Zhang, Jian; Zheng, Min

doi:10.1111/jdv.12034

Cited by 38 publications

(24 citation statements)

References 57 publications

(197 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, telogen effluvium during the early stages of using topical minoxidil has been reported. Providing explanation of this possibility to the patients is necessary because this may lead to discontinuation of topical application …”

Section: Cq3: Is Topical Application Of Minoxidil Effective?mentioning

confidence: 99%

Guidelines for the diagnosis and treatment of male‐pattern and female‐pattern hair loss, 2017 version

Manabe

Tsuboi

Itami

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the original goal of providing physicians and patients in Japan with evidence-based information for choosing efficacious and safe therapy for MPHL. Subsequently, new therapeutic drugs and treatment methods have been developed, and women's perception of MPHL has undergone change and the term "female-pattern hair loss (FPHL)" is becoming more common internationally. Thus, here we report a revised version of the 2010 guidelines aimed at both MPHL and FPHL. In these guidelines, finasteride 1 mg daily, dutasteride 0.5 mg daily and topical 5% minoxidil twice daily for MPHL, and topical 1% minoxidil twice daily for FPHL, are recommended as the first-line treatments. Self-hair transplantation, irradiation by light-emitting diodes and low-level lasers, and topical application of adenosine for MPHL are recommended, whereas prosthetic hair transplantation and oral administration of minoxidil should not be performed. Oral administration of finasteride or dutasteride are contraindicated for FPHL. In addition, we have evaluated the effectiveness of topical application of carpronium chloride, t-flavanone, cytopurine, pentadecane and ketoconazole, and wearing a wig. Unapproved topical application of bimatoprost and latanoprost, and emerging hair regeneration treatments have also been addressed. We believe that the revised guidelines will improve further the diagnostic and treatment standards for MPHL add FPHL in Japan.

show abstract

Section: Cq3: Is Topical Application Of Minoxidil Effective?mentioning

confidence: 99%

Guidelines for the diagnosis and treatment of male‐pattern and female‐pattern hair loss, 2017 version

Manabe

Tsuboi

Itami

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Patient satisfaction was fairly low in both regions, with almost one‐third of patients reporting dissatisfaction with the currently available male AGA treatments they had used. Patient satisfaction was higher for treatments such as minoxidil and 5‐ARI that are currently included in the international Asian consensus committee guideline than for traditional Chinese/herbal medicines and OTC treatments.…”

Section: Discussionmentioning

confidence: 99%

“…This suggests that most of the patients in the survey were suffering from male AGA. Additionally, all patients were receiving at least one medication for hair loss and 48.5% of patients were receiving at least one treatment recommended by international guidelines 15,16 for male AGA (minoxidil, 5-ARI).…”

Section: Discussionmentioning

confidence: 99%

Understanding patient and physician perceptions of male androgenetic alopecia treatments in Asia–Pacific and Latin America

Lulic

Inui

Sim

et al. 2017

The Journal of Dermatology

View full text Add to dashboard Cite

This survey aimed to explore patient and physician attitudes towards male androgenetic alopecia (AGA), satisfaction with currently available male AGA treatments and investigate the factors affecting treatment choice. The survey was carried out in five countries (Japan, South Korea, Taiwan, Mexico and Brazil) between November and December 2015 using a standard market research methodology. Questionnaires were completed by patients with male AGA or hair loss/thinning and practicing physicians who were responsible for prescribing AGA treatment. In total, 835 patients and 338 physicians completed the questionnaire. Overall, 37.6% of patients reported satisfaction with the treatments they had used. The highest patient satisfaction was reported for 5‐alpha‐reductase inhibitors (53.9% of patients satisfied). In all countries, physicians were more likely than patients to think that male AGA has a major impact on patient confidence (89.3% vs 70.4%, respectively). There was agreement by physicians and patients that male AGA patients who are involved in their treatment decisions have better outcomes. Patients who were satisfied with AGA treatments were more likely to have the level of involvement they desired in treatment decisions (69.1% of satisfied patients) than dissatisfied patients (56.4% of dissatisfied patients). This survey provides valuable insights into the attitudes of patients and physicians in Asia and Latin America about male AGA and its treatments. The survey identified areas of disconnect between physicians and patients regarding the impact of male AGA, treatment consultations and the importance of treatment attributes. It also highlights the need for physicians to spend sufficient time with patients discussing AGA treatment approaches.

show abstract

“…[12] The Asian Consensus Committee for AGA developed an algorithmic guideline, based on the BASP classification since the pre-existing classifications of AGA cannot easily classify the patterns of AGA that are more frequently seen in Asians. [13]…”

Section: Discussionmentioning

confidence: 99%

Application of the basic and specific classification on patterned hair loss in Indians

Agarwal¹,

Godse²,

Mahajan³

et al. 2013

Int J Trichol

View full text Add to dashboard Cite

Context:Several classifications for pattern hair loss (PHL) have been used over the years. The Norwood-Hamilton classification for men and Ludwig's classification for women is used commonly, but they have their limitations.Aims:The objective of the following study is to evaluate the efficacy of the basic and specific (BASP) classification in Indian populations.Subjects and Methods:We used the BASP classification to classify the PHL in the patients visiting our out-patient department in the period from June 2012 to May 2013. 763 patients were classified out of which 313 were females and 450 were males.Results:The majority of the female patients were in the 3-5th decade of life and in males were in 4-6th decade.Conclusions:The BASP classification is, easily remembered, reproducible classification for the diagnosis and treatment for both male and female pattern alopecia.

show abstract

Guidelines for management of androgenetic alopecia based on BASP classification–the Asian consensus committee guideline

Abstract: Background Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however,

Cited by 38 publications

References 57 publications

Guidelines for the diagnosis and treatment of male‐pattern and female‐pattern hair loss, 2017 version

Guidelines for the diagnosis and treatment of male‐pattern and female‐pattern hair loss, 2017 version

Understanding patient and physician perceptions of male androgenetic alopecia treatments in Asia–Pacific and Latin America

Application of the basic and specific classification on patterned hair loss in Indians

Contact Info

Product

Resources

About